BMS' Opdivo Heading Towards Indian Debut?
This article was originally published in Scrip
Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo (nivolumab) appears to be on course to a potential Indian debut, after a key local expert panel recommended the product for marketing.
You may also be interested in...
Roche’s cancer immunotherapy Tecentriq has received conditional marketing authorization under India’s layered approval process, setting the stage for a potential debut in the country. However, it remains to be seen how India’s evolving regulations in the area of clinical trial waivers could play out for such products.
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Fujifilm Toyama seals three-way deal to accelerate the development and global supply of favipiravir, close on the heels of the arrival of a generic version of the antiviral in India under restricted emergency use for the treatment of COVID-19.